/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced.
FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced.
14.12.2021 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today . Seite 1
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the Europ.